RxDoctor Payments Data

Cameron Oba, MD

Internal Medicine · San Jose, CANPI 1851357917

Payments from drug & device makers

$810in general payments, 2019–2025

Across 58 payments — averaging $13.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$175
  • Takeda Pharmaceuticals U.S.A., Inc.$105
  • Pfizer$81
  • Johnson & Johnson$70
  • AstraZeneca$68
  • Boehringer Ingelheim$46
  • plus $267 from 10 others

What the payments were for

  • Food & beverage$810100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$810 in reported general payments places this provider in the 70th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$325,650
Medicare patients
818
Services billed
3,526

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban116$112,644
OzempicSemaglutide33$53,218
JardianceEmpagliflozin40$48,111
JanuviaSitagliptin Phosphate27$39,591
XareltoRivaroxaban16$22,698
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$13,668
CreonLipase/Protease/Amylase11$8,180
Breo ElliptaFluticasone/Vilanterol18$6,675
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$6,292
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen227$6,090
AlvescoCiclesonide12$5,405
Atorvastatin Calcium480$5,041
SynthroidLevothyroxine Sodium52$4,008
Rosuvastatin Calcium167$3,866
Gabapentin196$3,565

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$81$114,073143 claims
Novo NordiskOzempic$46$53,21833 claims
Boehringer IngelheimJardiance$46$48,11140 claims
MerckJanuvia$15$39,59127 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$175$26,63653 claims
Johnson & JohnsonXarelto$70$22,69816 claims
AbbVieCreon, Synthroid$17$12,18763 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 13,581 internal medicine providers in California.

Other internal medicine in San Jose

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →